Clinical Trials Browser

INDUSTRY × Interventional × Vorinostat × Clear all

NCT02943642 2026-05-18

Resimmune®

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00875056 2026-01-30

MK-0683-103

Phase 2 Completed

56 enrolled 14 charts

Lymphoma

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 1 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03561259 2023-02-16

OPTIMUM

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

NCT00127127 2022-09-13

MK-0683-029

Phase 1 Completed

18 enrolled 24 charts

Neoplasms

NCT03713320 2022-04-08

SOLAR

Phase 2 Terminated

37 enrolled 23 charts

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00858234 2021-04-09

MK-0683-098

Phase 1 Completed

9 enrolled 9 charts

Multiple Myeloma

NCT00773838 2021-04-01

MK-0683-095

Phase 2 Completed

143 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT00642954 2020-11-18

MK-0683-074

Phase 1 Completed

31 enrolled 13 charts

Multiple Myeloma, Recurrence

NCT00128102 2020-10-26

MK-0683-014

Phase 3 Completed

661 enrolled 18 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT00109109 2019-11-14

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)

Phase 1 Terminated

Multiple Myeloma

NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Phase 1 Completed

DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

NCT00126451 2017-04-10

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Phase 2 Terminated

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT00097929 2017-04-07

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Phase 2 Completed

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00750178 2017-04-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Phase 1 Completed

Neoplasms

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase 2 Completed

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00423449 2016-02-04

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

Phase 1 Completed

61 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT00127140 2015-09-28

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Phase 1 Completed

Lymphoma

NCT00479232 2015-09-21

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

Phase 1 Completed

71 enrolled 9 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00373490 2015-08-27

A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)

Phase 1 Completed

16 enrolled 13 charts

Neoplasms

NCT00632931 2015-07-30

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Phase 1 Completed

25 enrolled 21 charts

Advanced Cancer Relapsed

NCT00473889 2015-07-03

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

Phase 2/3 Terminated

253 enrolled 13 charts

Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00111813 2015-05-21

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Phase 1 Completed

34 enrolled 10 charts

Multiple Myeloma

NCT00907738 2015-05-21

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Phase 2 Completed

27 enrolled 9 charts

Advanced Cancer

NCT00127101 2015-04-21

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Phase 1 Terminated

23 enrolled 13 charts

Lymphoma

NCT00771472 2015-04-21

Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)

Phase 1 Completed

10 enrolled 11 charts

Lymphoma

NCT00424775 2015-04-20

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Phase 1 Terminated

3 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00251589 2015-03-06

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Phase 1/2 Terminated

23 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT00791011 2014-03-05

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Phase 1 Completed

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00106626 2009-04-22

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Phase 1 Completed

52 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung